HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment vs Tata India Pharma and Healthcare Fund Direct Plan Growth
NAV, returns and costs — not a recommendation.
 HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment |  Tata India Pharma and Healthcare Fund Direct Plan Growth | |
|---|---|---|
| NAV | ₹21.944 | ₹38.3028 |
| NAV date | 2026-09-30 | 2026-09-30 |
| 1 year | +27.80% | +9.46% |
| 3 year (p.a.) | +30.22% | +18.81% |
| 5 year (p.a.) | +30.22% | +14.16% |
| Expense ratio | 0.92% | 0.67% |
| Fund size | ₹2362.44 Cr | ₹1386.99 Cr |
| Risk | — | — |
| Category | Sectoral Pharma and Healthcare | Sectoral Pharma and Healthcare |
Past performance does not guarantee future returns. Mutual fund investments are subject to market risks.